Related references
Note: Only part of the references are listed.Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
Roland Martin
CLINICAL IMMUNOLOGY (2012)
Construction and expression of anti-Tn-antigen-specific single-chain antibody genes from hybridoma producing MLS128 monoclonal antibody
Noriyuki Yuasa et al.
JOURNAL OF BIOCHEMISTRY (2012)
Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In Vivo
Torsten Ruelker et al.
PLOS ONE (2012)
Interleukin-2/Interleukin-2 Antibody Therapy Induces Target Organ Natural Killer Cells That Inhibit Central Nervous System Inflammation
Junwei Hao et al.
ANNALS OF NEUROLOGY (2011)
Production and characterization of LEA29Y, a variant of cytotoxic T-lymphocyte antigen 4-immunoglobulin, in Pichia pastoris
Lin Wan et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2011)
Optimizing Therapeutic Antibody Function Progress with Fc Domain Engineering
Etsuji Kaneko et al.
BIODRUGS (2011)
Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
Xinhui Wang et al.
CANCER RESEARCH (2011)
Emerging drugs for uveitis
Theresa Larson et al.
EXPERT OPINION ON EMERGING DRUGS (2011)
Antibody therapy for Adult T-cell leukemia-lymphoma
Takashi Ishida et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
Simone C. Wuest et al.
NATURE MEDICINE (2011)
Rise and Fall of an Anti-MUC1 Specific Antibody
Holger Thie et al.
PLOS ONE (2011)
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
Eric J. Lepin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation
Maya Campara et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
Jayne F. Martin et al.
JOURNAL OF IMMUNOLOGY (2010)
Monoclonal antibodies in MS Mechanisms of action
Bibiana Bielekova et al.
NEUROLOGY (2010)
How antibodies fold
Matthias J. Feige et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Strategies and challenges for the next generation of therapeutic antibodies
Alain Beck et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Roland E. Kontermann
BIODRUGS (2009)
Engineered therapeutic antibodies with improved effector functions
Tsuguo Kubota et al.
CANCER SCIENCE (2009)
Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas
Tove Olafsen et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology
Pieter P. Jacobs et al.
NATURE PROTOCOLS (2009)
High-level expression of a functional humanized single-chain variable fragment antibody against CD25 in Pichia pastoris
Lin Wan et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2008)
Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody C(H)3 domain
Arnold MaAuley et al.
PROTEIN SCIENCE (2008)
Daclizumab
Marcus Mottershead et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Anti-tac (daclizumab, zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey
Thomas A. Waldmann
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Antibodies and gene therapy: teaching old 'magic bullets' new tricks
L Sanz et al.
TRENDS IN IMMUNOLOGY (2004)
Effect of pegylation on pharmaceuticals
JM Harris et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Share Paper
